Burrill on Biotech - BioPharm International

ADVERTISEMENT

Burrill on Biotech

Global Economic Woes Overshadow Biotech Industry Advances in 2011

January 1, 2012

Greater emphasis on focus and efficiency for companies as market demands value in 2012.

Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings

October 1, 2011

Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings

Biotech Posts Strong Gains

July 1, 2011

Strong pipelines, approvals, and deals drive up market cap.

Biotech Starts the Year Positively

April 1, 2011

Industry starts the year with a positive spin.

Biotech Writes its New "Play Book"

January 1, 2011

Business models that were used to create current value are no longer going to be effective going forward.

Biotech Cools Off as Capital Markets Weaken

October 1, 2010

Biotech's mid-sized elites position themselves for growth.

Capital Market's Woes Weigh Heavily on Biotech

July 1, 2010

After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.

Biotech on a Roll to Start 2010

April 1, 2010

As the capital markets in the US and globally continue to strengthen, the biotech industry can expect to see a rise in initial public offerings this year.

Biotech Remains Upbeat During the Summer

October 1, 2009

Biotech impressed investors with positive drug data, strong drug sales and earnings, and partnering deals.

ADVERTISEMENT

ADVERTISEMENT

Click here